Quantum Pharma Plc develops, manufactures, and supplies niche pharmaceutical products to the retail pharmacy, pharmaceutical wholesaler, hospital, and homecare markets in the United Kingdom and other European countries. It operates through three segments: Specials, Niche Pharmaceuticals, and Medication Adherence. The company’s Specials segment manufactures, sources, and supplies special medicines to pharmacies, pharmaceutical wholesalers, hospitals, and other specials suppliers. Its Niche Pharmaceuticals segment develops and supplies niche pharmaceuticals; and provide development and regulatory services, and out-license products and dossiers to third parties. The company’s Medication Adherence segment provides products and services to enhance adherence to medication regimes, as well as offers patient-focused homecare services and services to pharmaceutical companies. It also operates an aseptics compounding unit that manufactures bespoke intravenous specials; and develops, licenses, and commercializes medicines primarily those currently prescribed as specials. In addition, the company supplies and distributes body care products; supplies prescription drugs to the home care sector; and supplies Biodose MDS system to pharmacies, as well as provides batch manufacturing services for unlicensed pharmaceutical products. Quantum Pharma Plc was founded in 2004 and is headquartered in Burnopfield, the United Kingdom. As of November 1, 2017, Quantum Pharma Plc operates as a subsidiary of Clinigen Group Plc.